Quarterly report · Q2
4544.TEDINET S100PJXC
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥134.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥272.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥133.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥17.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥27.0bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥17.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥47.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.7bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥20.7bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥25.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥19.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥15.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥19.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥285.9bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥286.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥271.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥128.6bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥146.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥157.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥140.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥130.9bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥37.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥37.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥41.8bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥15.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥55.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥20.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥18.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥30.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥21.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥273.42 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.17 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥519.55 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥342.23 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.93 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥273.38 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥519.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥342.1 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 55.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥5.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥85.1bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥85.0bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥83m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥40.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥35.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥15.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥604m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥139.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥134.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥19.2bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥4.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥4.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥746m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥88.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥88.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥33m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥35.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥12.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥14.7bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥10m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥138.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥133.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.9bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥27.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 532
| Item | Context | Value | Unit |
|---|---|---|---|
| Loss gain on step acquisitions ope cf | Prior1YTDDuration | － | JPY |
| Loss gain on step acquisitions ope cf | CurrentYTDDuration | -758000000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | Prior1YTDDuration | -4000000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | CurrentYTDDuration | -853000000 | JPY |
| Decrease increase in other current assets ope cf | Prior1YTDDuration | -3484000000 | JPY |
| Decrease increase in other current assets ope cf | CurrentYTDDuration | -758000000 | JPY |
| Increase decrease in other current liabilities ope cf | Prior1YTDDuration | 91000000 | JPY |
| Increase decrease in other current liabilities ope cf | CurrentYTDDuration | -4465000000 | JPY |
| Other net ope cf | Prior1YTDDuration | 1108000000 | JPY |
| Other net ope cf | CurrentYTDDuration | -771000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 21987000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 21705000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -981000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -5849000000 | JPY |
| Other net ope cf subtotal | Prior1YTDDuration | -149000000 | JPY |
| Other net ope cf subtotal | CurrentYTDDuration | -95000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 20856000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 15760000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -10533000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -8102000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YTDDuration | 303000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYTDDuration | 2680000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -6426000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -3453000000 | JPY |
| Proceeds from share of profits on investments in capital inv cf | Prior1YTDDuration | 3563000000 | JPY |
| Proceeds from share of profits on investments in capital inv cf | CurrentYTDDuration | － | JPY |
| Purchase of investments in subsidiaries inv cf | Prior1YTDDuration | － | JPY |
| Purchase of investments in subsidiaries inv cf | CurrentYTDDuration | -8273000000 | JPY |
| Subsidies received inv cf | Prior1YTDDuration | 1696000000 | JPY |
| Subsidies received inv cf | CurrentYTDDuration | － | JPY |
| Other net inv cf | Prior1YTDDuration | -1392000000 | JPY |
| Other net inv cf | CurrentYTDDuration | -1519000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -12788000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -18668000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -2087000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -1811000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -5362000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -3596000000 | JPY |
| Repayments of finance lease obligations fin cf | Prior1YTDDuration | -1888000000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYTDDuration | -2101000000 | JPY |
| Other net fin cf | Prior1YTDDuration | 49000000 | JPY |
| Other net fin cf | CurrentYTDDuration | 76000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -9289000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -7432000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 79000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 1136000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -1141000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -9204000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 42950000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 46479000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |